Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect study of SPH5030 in healthy volunteers
NCT06372223Phase 1Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Mar 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sph5030 in HER2-positive solid tumor (HER2+) (2 arms), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoints: Peak Plasma Concentration at 2 months, Peak time at 2 months and 1 more. Started Mar 2024; status: completed.
02
Drugs
sph5030
03
Conditions
HER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT06372223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06372223.